舒泰神(300204) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 72.91% to CNY 22,062,416.11 for the current period[8] - Operating revenue fell by 49.55% to CNY 189,806,004.82 compared to the same period last year[8] - Basic earnings per share decreased by 70.59% to CNY 0.05 for the current period[8] - The weighted average return on equity decreased by 3.15% to 0.92% for the current period[8] - Total operating revenue for Q3 2018 was ¥189.81 million, a decrease of 49.6% compared to ¥376.19 million in the same period last year[42] - Net profit for Q3 2018 was ¥22.06 million, a decline of 72.8% from ¥81.12 million in Q3 2017[44] - The company's total revenue for the third quarter was ¥189,806,004.82, a decrease of 49.6% compared to ¥376,151,969.44 in the same period last year[47] - The net profit for the current period is ¥134,099,132.98, down from ¥235,463,147.62 in the previous period, representing a decline of approximately 43%[56] - The total profit for the current period is ¥157,948,503.15, down from ¥272,109,641.61, marking a decline of about 42%[56] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 14.39% to CNY 180,407,693.32 year-to-date[8] - Cash and cash equivalents increased by CNY 167,211,256.41, a growth of 41.68%, primarily due to the recovery of matured financial products[18] - The cash received from operating activities increased by CNY 25,555,517.63, a growth of 190.20%, mainly due to a temporary refund received[22] - Cash and cash equivalents at the end of the period stand at ¥568,403,447.59, down from ¥704,136,308.90[60] - The cash inflow from investment activities for the current period is ¥2,138,929,471.93, compared to ¥1,341,309,940.03 in the previous period, showing an increase of approximately 59%[59] - The cash outflow from investment activities increased to ¥2,010,646,819.86 from ¥1,087,384,835.62, indicating a rise of about 85%[59] - The net cash flow from financing activities was -128,158,150.85 CNY, compared to -89,723,246.95 CNY in the previous period, indicating a decrease of approximately 43%[63] - The company experienced a net increase in cash and cash equivalents of 158,307,067.06 CNY during the quarter[63] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,086[11] - The largest shareholder, Yizhao (Beijing) Investment Co., Ltd., holds 37.15% of the shares[11] - The company plans to repurchase shares worth between RMB 50 million and RMB 200 million, with a maximum price of RMB 15 per share, within 12 months from the approval date[25] - The company distributed a cash dividend of RMB 2.50 per 10 shares, totaling approximately RMB 119.45 million for the 2017 fiscal year[28] Assets and Liabilities - Total assets increased by 5.43% to CNY 2,771,286,761.01 compared to the end of the previous year[8] - Cash and cash equivalents increased to approximately RMB 568.4 million from RMB 401.2 million at the beginning of the period, reflecting a growth of about 42%[35] - Total assets decreased to ¥2.51 billion from ¥2.59 billion, a reduction of 3.9%[41] - Total liabilities decreased to ¥324.26 million from ¥419.69 million, a decline of 22.7%[40] - Non-current assets totaled approximately RMB 1.18 billion, up from RMB 808 million at the beginning of the period, marking an increase of about 46%[36] Expenses and Costs - The company’s sales expenses decreased by CNY 343,687,395.98, a decline of 48.22%, due to reduced sales revenue and enhanced cost control measures[20] - Total operating costs for Q3 2018 were ¥175.52 million, down 39.9% from ¥291.35 million year-on-year[42] - The total operating costs for the quarter were ¥20,018,410.36, a slight decrease from ¥21,889,634.90 in the previous year[47] - The company experienced a decrease in sales expenses, which were ¥115,839,938.13, down from ¥237,800,233.01 year-over-year[47] Research and Development - Research and development expenses for Q3 2018 were ¥30.06 million, up 40.5% from ¥21.42 million in the previous year[42] - Research and development expenses increased to ¥67,486,174.04 from ¥55,435,554.11, reflecting a growth of about 22%[55] Other Income and Comprehensive Income - The company reported a total of CNY 5,875,695.73 in government subsidies recognized during the period[9] - Other comprehensive income increased by CNY 212,412,121.31, a growth of 119.31%, mainly due to the fair value increase of investments in InflaRx GmbH[19] - Other comprehensive income after tax for Q3 2018 was ¥51.58 million, compared to a loss of ¥4.49 million in the same period last year[44] - The company reported a significant increase in other income to ¥1,307,431.80 from ¥172,500.00 year-over-year[48] Capital and Investments - The company’s investment cash outflow increased by CNY 869,238,360.00, an increase of 81.48%, primarily due to increased purchases of financial products[22] - The company completed a capital increase of $10 million for its wholly-owned subsidiary Staidson BioPharma Inc. in the U.S., aimed at compensating core technical personnel and purchasing key research project materials and equipment[24] - Long-term equity investments increased to ¥681.62 million from ¥517.15 million, an increase of 31.7%[39] Audit and Compliance - The company did not undergo an audit for the third quarter report, which may affect the reliability of the financial data presented[64] - There were no violations regarding external guarantees during the reporting period[29] - The company has no overdue commitments from major shareholders or related parties during the reporting period[27]